Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.43 |
| ▸ | MVD | P53602 | 3/20 | 0.33 |
| ▸ | FNTA | P49354 | 3/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16855741 | 1.00 | FDPS (0.47) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL687243 | 1.00 | FDPS (0.47) | FDPSBLMTDP1BTN3A1MVD | |
| Ammonia Solution, Strong SCHEMBL28227868 | 0.97 | FDPS (0.45) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL9580811 | 0.97 | FDPS (0.45) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL10862597 | 0.97 | FDPS (0.45) | FDPSBLMTDP1BTN3A1MVD | |
| Ammonia Solution, Strong SCHEMBL28227867 | 0.97 | FDPS (0.45) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL19387807 | 0.94 | FDPS (0.53) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL889928 | 0.94 | FDPS (0.53) | FDPSBLMTDP1BTN3A1MVD | |
| Ammonia Solution, Strong SCHEMBL28569612 | 0.92 | FDPS (0.50) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL1577193 | 0.92 | FDPS (0.50) | FDPSBLMTDP1BTN3A1MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114736260-B | Preparation method of nucleotide triphosphate | 上海吉量医药工程有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-118165342-A | Flame-retardant polyurethane heat-insulating core material and preparation method thereof | 娄底潇湘职业学院 | 2024-06-11 | — | — | CN | claimed |
| CN-114656511-B | Process for the preparation of acetylated cytosine triphosphates and intermediates therefor | 上海吉量医药工程有限公司 | 2024-04-16 | — | — | CN | claimed |
| WO-2023185812-A1 | METHOD FOR PREPARING ACETYLATED CYTOSINE TRIPHOSPHATE AND INTERMEDIATE THEREOF | 上海吉量医药工程有限公司 | 2023-10-05 | — | — | WO | claimed |
| WO-2023185814-A1 | METHOD FOR PREPARING NUCLEOTIDE TRIPHOSPHATE | 上海吉量医药工程有限公司 | 2023-10-05 | — | — | WO | claimed |
| CN-114736260-A | Preparation method of nucleotide triphosphate | 上海吉量医药工程有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114656511-A | Preparation method of acetylated cytosine triphosphate and intermediate thereof | 上海吉量医药工程有限公司 | 2022-06-24 | — | — | CN | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12247046-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | TRANSLATE BIO, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| CN-119431334-A | Preparation method of 2' OMe modified pseudouridine and N1 methyl pseudouridine | 上海吉量医药工程有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4493573-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | Rome Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240415923-A1 | RNA-Dependent RNA Polymerase Inhibitory Compounds, Uses in Managing Viral Infections, and Pharmaceutical Compositions | UNIV EMORY (US) | 2024-12-19 | — | — | US | disclosed |
| US-20030138805-A1 | Thermostable chimeric nucleic acid polymerases and uses thereof | QIAGEN GMBH (DE) | 2003-07-24 | — | — | US | disclosed |
| US-6503710-B2 | Providing an amount of DNA containing the mutation, adding primers and a set of modified non-terminating nucleotide triphosphates (NTP) and terminating nucleotide triphosphates for the method of primer extension; hybridization; decomposing | BRUKER DALTONIK GMBH (DE) | 2003-01-07 | — | — | US | disclosed |
| EP-1259624-A2 | THERMOSTABLE CHIMERIC NUCLEIC ACID POLYMERASES AND USES THEREOF | QIAGEN GmbH (DE) | 2002-11-27 | — | — | EP | disclosed |
| US-20020162622-A1 | Providing an amount of DNA containing the mutation, adding primers and a set of modified non-terminating nucleotide triphosphates (NTP) and terminating nucleotide triphosphates for the method of primer extension; hybridization; decomposing | BRUKER DALTONIK GMBH (DE) | 2002-11-07 | — | — | US | disclosed |
| WO-2001061015-A2 | THERMOSTABLE CHIMERIC NUCLEIC ACID POLYMERASES AND USES THEREOF | QIAGEN GMBH (DE) | 2001-08-23 | — | — | WO | disclosed |
| US-5354656-A | Method of DNA sequencing | STRATAGENE (US) | 1994-10-11 | — | — | US | disclosed |
| WO-1991005065-A1 | AN IMPROVED METHOD OF DNA SEQUENCING | STRATAGENE (US) | 1991-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247046-B2 | Ribonucleic acids with 4′-thio-modified nucleotides and related methods | RNMT, RNGTT, NSUN3 | FDPS 1030/4885BLM 2092/4885TDP1 402/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | FDPS 1226/4885BLM 2901/4885TDP1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.